How to Take Retatrutide (2026)

Gather everything before you start:

• Retatrutide vial (lyophilized powder, 5mg or 10mg)
• Bacteriostatic water (0.9% benzyl alcohol preserved)
• Insulin syringes: 29 to 31 gauge, 0.5 inch needle, 1mL capacity
• Alcohol swabs (70% isopropyl alcohol)
• Sharps container for used needles
• Fine-tip marker for labeling the vial

Use bacteriostatic water, not sterile water. The benzyl alcohol preservative prevents bacterial growth for up to 30 days. Sterile water has no preservative and risks contamination within 24 to 48 hours. For sourcing, see where to buy bacteriostatic water for injection. For the difference between the two, see bacteriostatic water vs sterile water.

1. 1.Remove the plastic cap from the retatrutide vial to expose the rubber stopper.
2. 2.Swab the stopper with an alcohol pad. Let it air dry for 10 seconds.
3. 3.Draw bacteriostatic water into a syringe. For a 10mg vial, draw 1mL to create a 10mg/mL concentration (easiest for weekly dosing).
4. 4.Insert the needle through the rubber stopper at a slight angle.
5. 5.Release the water slowly down the inside wall of the vial. Never spray it directly onto the powder. Direct impact can denature the peptide structure.
6. 6.Swirl gently in small circular motions. Never shake. Shaking creates foam and causes aggregation that reduces potency.
7. 7.Wait until the powder is fully dissolved. The solution should be clear and colorless. If slightly cloudy, refrigerate for 15 to 30 minutes and swirl again.
8. 8.Label the vial with the date, concentration (e.g., "10mg/1mL"), and your name if storing alongside other peptides.
9. 9.Refrigerate immediately at 2 to 8 degrees Celsius.

Use the peptide reconstitution calculator for custom vial sizes and water volumes.

The amount of water you add determines how many units you draw per dose. Choosing the right dilution makes weekly dosing practical across all titration levels.

For the 8mg and 12mg maintenance doses, the 10mg/mL concentration (10mg vial + 1mL water) is most practical. At 10mg/mL, 8mg equals 80 units in a single 1mL syringe draw. For 12mg, you need two draws (80 units + 40 units from a fresh vial or the same vial if enough remains).

For automated volume calculations, use the peptide unit converter.

Every person begins at 2mg once weekly, regardless of body weight, prior GLP-1 experience, or target maintenance dose. This is non-negotiable based on the clinical evidence.

What 2mg does: The GLP-1 receptor activation begins suppressing appetite within 2 to 3 days of the first injection. You will likely notice that portion sizes feel larger than usual, and cravings for calorie-dense foods may diminish. The GIP component starts improving insulin signaling. The glucagon component is active but at a low enough level to let your liver adapt gradually.

Expected side effects at 2mg: Mild nausea in the first 2 to 3 days (resolves by day 5 for most people), reduced appetite, and occasionally loose stools. If nausea is more than mild, see the side effect management section below.

Weight loss at this phase: Modest. In the Phase 2 trial, participants on the 12mg track had lost approximately 3 to 5% of body weight by the end of week 4. The real acceleration comes later. Do not evaluate the drug's effectiveness at this stage.

If you have used semaglutide or tirzepatide previously, you still start at 2mg. Prior GLP-1 tolerance does not eliminate the need for retatrutide-specific titration because the glucagon receptor component is entirely new to your body. For more on switching between these drugs, see semaglutide to tirzepatide switching.

At week 5, double the dose to 4mg once weekly. Appetite suppression becomes noticeably stronger. Most users report a meaningful reduction in food cravings and a natural shift toward smaller meals.

What changes at 4mg: GLP-1 receptor activation intensifies, further slowing gastric emptying. GIP-mediated metabolic improvements become more pronounced. You may notice that meals you previously finished easily now leave you uncomfortably full halfway through. This is the drug working as intended.

Expected side effects: GI symptoms may briefly return during the first 1 to 2 weeks at the new dose. Nausea, diarrhea, and reduced appetite are the most common. These typically resolve within 7 to 10 days as the GI tract adapts. If symptoms remain severe after 2 weeks, hold at 4mg for an additional 2 to 4 weeks before escalating.

Weight loss at this phase: Accelerating. The Phase 2 trial showed the 4mg group lost 12.9% of body weight by week 24. By the end of week 8, you should see measurable changes on the scale and in how clothing fits. For detailed weight loss data by dose, see the retatrutide dosage guide.

At week 9, the dose increases to 8mg once weekly. This is where the glucagon receptor activation becomes more pronounced and energy expenditure increases measurably.

What changes at 8mg: The thermogenic effect of glucagon receptor activation becomes a meaningful contributor to weight loss. Your body burns more calories at rest. Liver fat oxidation accelerates. The Phase 2 trial showed the 8mg group achieved 22.8% body weight loss at 48 weeks, only 1.4 percentage points less than the 12mg group.

Decision point: For some individuals, 8mg is the optimal maintenance dose. If side effects are tolerable and weight loss is progressing well, there is no strict requirement to escalate to 12mg. Discuss this with your healthcare provider based on your response, goals, and tolerability.

Expected side effects: Similar pattern as the previous escalation. Transient nausea and GI discomfort that resolve within 1 to 2 weeks. At 8mg, a small percentage of users report dysesthesia (altered skin sensation, tingling, or numbness). This was noted in the Phase 2 trial and appears to be dose-dependent. For a full breakdown of side effects by dose, see retatrutide side effects.

At week 13, the dose reaches 12mg once weekly. This is the maximum studied dose and the one that produced the strongest results in every clinical trial.

Clinical results at 12mg:

Every single participant on 12mg lost at least 5% of their body weight, a response rate no other obesity medication has achieved (Jastreboff et al., NEJM 2023).

Continue the 12mg maintenance dose for as long as treatment is needed. The Phase 3 TRIUMPH-4 trial showed continued weight loss at 68 weeks with no plateau, suggesting longer treatment durations may produce even greater reductions.

Some practitioners prefer a more gradual escalation using 2mg increments every four weeks. This approach is useful if you have a history of poor GLP-1 tolerance, experienced significant nausea on tirzepatide or semaglutide, or simply prefer a conservative approach.

This schedule takes 20 weeks to reach full dose instead of 12. The tradeoff is slower initial weight loss in exchange for fewer GI side effects during each escalation. For patients who quit tirzepatide due to nausea, this gentler approach often makes the difference between completing the protocol and abandoning it.

1. 1.Wash your hands with soap and water for at least 20 seconds.
2. 2.Remove the vial from the refrigerator. If the solution is very cold, let it sit at room temperature for 2 to 3 minutes. Cold injections sting more than room-temperature ones.
3. 3.Swab the vial stopper with an alcohol pad and let it air dry for 10 seconds.
4. 4.Pull back the syringe plunger to the number of units you need for your current dose.
5. 5.Insert the needle through the center of the rubber stopper.
6. 6.Push air into the vial to equalize pressure and make drawing easier.
7. 7.Invert the vial so the needle tip is submerged in liquid.
8. 8.Pull the plunger back slowly to your target volume. If you see air bubbles, flick the syringe gently and push them back into the vial.
9. 9.Withdraw the needle from the vial.

Double-check your volume against the concentration table above before injecting. A miscalculation here means injecting half or double your intended dose.

Three subcutaneous injection sites are standard for retatrutide:

Abdomen: The most common site. Pinch a fold of skin at least 2 inches from the navel. Avoid the area directly around the belly button. This site has the most consistent subcutaneous fat layer and is the easiest for self-injection.

Front of thigh: The middle third of the upper leg, on the outer or front surface. Good alternative when the abdomen is sore. Avoid the inner thigh where larger blood vessels run closer to the surface.

Back of upper arm: The fatty area on the outer, upper portion of the arm. Harder to self-inject without assistance, but viable with practice or a helper.

Rotation is mandatory. Do not inject in the same spot two weeks in a row. Repeated injections in the same location cause lipodystrophy (localized fat tissue changes), inflammation, and inconsistent absorption. Rotate between all three sites on a weekly cycle: abdomen one week, right thigh the next, left thigh the next, upper arm the next. For more on injection site reactions and how to manage them, see tirzepatide injection site reaction.

1. 1.Swab the injection site with a fresh alcohol pad. Let it air dry completely. Injecting through wet alcohol stings and can irritate the tissue.
2. 2.Pinch a fold of skin between your thumb and index finger. This lifts the subcutaneous fat away from the muscle layer beneath.
3. 3.Insert the needle at a 45-degree angle in one smooth, confident motion. Hesitating or jabbing increases discomfort.
4. 4.Release the skin pinch.
5. 5.Push the plunger slowly and steadily over 5 to 10 seconds. Rushing creates pressure buildup that causes stinging and post-injection lumps.
6. 6.Count to 5 with the needle still inserted. This allows the liquid to disperse before withdrawal.
7. 7.Withdraw the needle at the same angle you inserted it.
8. 8.Press gently with a clean cotton pad if there is any bleeding. Do not rub the site, as rubbing can push the peptide out of the subcutaneous layer.
9. 9.Dispose of the syringe in a sharps container immediately. Never recap or reuse needles.

The entire process takes under 2 minutes. Most users describe the sensation as a brief pinch followed by nothing. If you experience burning, the solution may be too cold. Let the vial warm at room temperature for 3 to 5 minutes before drawing your next dose. For comprehensive peptide injection safety protocols, see the peptide safety guide.

Pick one day per week and stick with it. The specific day does not matter pharmacologically. Most users choose a day that is easy to remember and when they are home: Sunday morning, Monday evening, or Friday afternoon are common choices.

Consistency is more important than optimization. Injecting every Monday at 8 AM is better than injecting whenever you remember, even if some other day would be theoretically optimal. Set a recurring alarm on your phone.

If you miss your scheduled day, inject as soon as you remember within 3 days. If more than 3 days have passed since the missed dose, skip it entirely and resume on the next scheduled day. Do not double up on doses.

Both work. The data from clinical trials does not indicate a significant difference in efficacy based on time of day. However, practical considerations favor one over the other depending on your lifestyle.

Evening injection (after dinner): Many users prefer injecting after their last meal of the day. The reason is strategic: GLP-1 activation peaks within hours of injection, and any nausea tends to be strongest during this window. If you inject at 8 PM and go to sleep at 10 PM, you sleep through the worst of any GI discomfort. By morning, the nausea has typically passed.

Morning injection: Preferred by users who do not experience significant nausea. Morning injection allows you to monitor for any injection site reactions during waking hours. Some users report that appetite suppression feels stronger when the injection aligns with the start of the eating day.

There is no wrong answer. Try one timing for 2 to 3 weeks and switch if it does not suit your schedule or symptom pattern.

Retatrutide can be injected with or without food. The clinical trials did not require fasting or specific meal timing around injection, and absorption is not meaningfully affected by food intake.

Practical meal guidelines during retatrutide use:

• Eat smaller, more frequent meals. Five small meals per day works better than three large ones when gastric emptying is slowed. A large meal on top of delayed emptying is the fastest route to nausea.
• Prioritize protein. Retatrutide produces significant weight loss, and protein intake protects muscle mass during caloric deficit. Aim for 0.7 to 1.0 grams of protein per pound of goal body weight daily (Heymsfield et al., 2024).
• Reduce dietary fat on injection day. Fat is the slowest macronutrient to digest. Combining high-fat meals with GLP-1-mediated gastric slowing amplifies nausea risk.
• Stay hydrated. Aim for at least 2 to 3 liters of water daily. GI side effects like diarrhea and vomiting can cause dehydration, and retatrutide's appetite suppression may reduce your natural thirst cues.
• Avoid alcohol within 24 hours of injection. Alcohol adds a second GI stressor on top of the drug's gastric effects. There is no published interaction data, but the pharmacological reasoning is straightforward: delayed gastric emptying plus alcohol equals amplified nausea.

Lyophilized peptide is relatively resilient. A few hours at room temperature during shipping will not destroy the product. But once it arrives, store it in the refrigerator or freezer immediately. If you plan to use the vial within a few weeks, refrigerate. If storing for months, freeze.

Once reconstituted, the clock starts. Write the date on the vial with a marker. Remove the vial from the fridge only long enough to draw your dose (under 2 minutes), then return it immediately.

A 10mg vial at 12mg per week provides less than 1 full week of dosing at maintenance. Plan your vial purchases accordingly. During the 2mg starting phase, a single 10mg vial lasts 5 weeks (5 doses). At 12mg maintenance, you need more than one 10mg vial per week unless you source larger vials. For shelf life details, see how long do reconstituted peptides last.

Most first-week nausea on retatrutide is not the violent, debilitating kind. It is a persistent low-grade queasiness, like the feeling you get after eating one too many bites at a buffet. Some people describe it as fullness that borders on discomfort rather than actual nausea.

At the 2mg starting dose, roughly 30 to 40% of users experience some GI discomfort. Of those, the majority describe it as mild. Severe nausea requiring intervention occurs in fewer than 10% of participants at the starting dose. The discomfort typically peaks on days 2 to 3 after the first injection and resolves by day 5 to 7.

If you feel nothing at all during the first week, that is normal too. Absence of side effects does not mean the drug is not working. Some people simply tolerate GLP-1 activation well. The appetite suppression will still build over the coming weeks.

The inflection point for most users occurs between weeks 4 and 8. By this time, you have been on 2mg for a month and then moved to 4mg. Cumulative caloric deficit from sustained appetite suppression starts producing visible changes.

Clothing becomes noticeably looser. The number on the scale drops consistently. Friends and family begin commenting. In the Phase 2 trial, participants on the highest dose track had lost an average of 12.9% body weight by week 24, with much of that acceleration happening between weeks 4 and 16.

This is also when the psychological shift happens. You stop thinking about food as much. The mental chatter about what to eat next, the cravings for sugar and fried food, the urge to snack at 10 PM, these gradually quiet. This is not willpower. It is GLP-1 and GIP modulating hypothalamic appetite circuits. The drug changes the signal, and the behavior follows.

Between months 3 and 6, you are at or near the 12mg maintenance dose. This is where retatrutide's third receptor separates it from every other weight loss drug.

With semaglutide, weight loss typically slows around this timepoint as metabolic adaptation kicks in. Your resting metabolic rate drops, leptin decreases, ghrelin increases, and the body fights to restore lost weight. GLP-1 alone cannot fully overcome this compensation. For more on this pattern, see semaglutide before and after.

Retatrutide counteracts metabolic adaptation through glucagon receptor activation. Glucagon stimulates thermogenesis and hepatic fat oxidation, increasing resting energy expenditure by an estimated 15 to 20% (Habegger et al., 2010). Your body tries to conserve energy. Glucagon forces it to burn more. This is why the retatrutide weight loss curve continues climbing when semaglutide's curve flattens.

The liver fat data illustrates this vividly. In the MASLD substudy, retatrutide 12mg reduced liver fat by 82.4% at 48 weeks. Nearly 80% of participants saw their liver fat drop below the 5% threshold defining a healthy liver (Hartman et al., Nature Medicine 2024). No GLP-1-only drug comes close to this level of hepatic fat clearance.

Data from the Phase 2 trial provides dose-specific safety data (Jastreboff et al., NEJM 2023):

The majority of GI events were classified as mild to moderate and were partially mitigated by the gradual titration protocol. Serious adverse events requiring hospitalization were rare across all dose groups.

Eat smaller meals. This is the single most effective countermeasure. Large meals overwhelm a stomach that is emptying 30 to 40% slower than normal. Five small meals of 300 to 400 calories each outperforms three meals of 600 to 800 calories.

Avoid high-fat foods on injection day and the day after. Fat takes the longest to digest. When gastric emptying is already delayed, dietary fat sits in the stomach and amplifies nausea.

Time your injection after your last meal. Injecting at bedtime means any nausea peaks during sleep. By morning, the acute phase has typically passed.

Stay hydrated aggressively. Diarrhea and vomiting deplete fluids faster than you think. Add electrolytes if needed. Aim for 2.5 to 3 liters of water daily.

Ginger tea or ginger chews. Ginger has modest antiemetic properties. No clinical data specific to GLP-1 agonist nausea, but no risk and anecdotally helpful.

Delay escalation if needed. If side effects at any dose level remain intolerable after 2 weeks, hold at the current dose for an additional 2 to 4 weeks before escalating. The Phase 2 trial protocol permitted dose delays for this reason. Reaching 12mg in 16 weeks instead of 12 will not compromise your long-term results.

For a comprehensive breakdown of each side effect and its management, see retatrutide side effects.

Retatrutide has a strong safety profile in clinical trials, but certain symptoms require immediate medical evaluation:

• Persistent vomiting that prevents keeping fluids down for more than 24 hours. Dehydration from prolonged vomiting can become dangerous quickly.
• Severe abdominal pain that differs from typical nausea. This could indicate pancreatitis, which has been reported rarely with GLP-1 agonists as a class (Egan et al., 2022).
• Signs of allergic reaction: hives, swelling of face or throat, difficulty breathing. Stop the drug and seek emergency care.
• Significant injection site reaction: redness that spreads beyond 3 cm, warmth, hardening, or pus. These suggest infection, not a normal reaction.
• Sudden vision changes. While not specifically reported in retatrutide trials, rapid weight loss with GLP-1 agonists has been associated with diabetic retinopathy progression in patients with pre-existing diabetes (Davies et al., NEJM 2017).

Do not attempt to manage these symptoms at home. Contact your healthcare provider immediately.

Mistake 1: Skipping the 2mg starting phase. The most common and most consequential error. Starting at 4mg or 8mg because you "already tolerated semaglutide" ignores the fact that retatrutide adds glucagon receptor activation. The Phase 2 trial proved that skipping the 2mg start nearly doubled GI side effect rates. Every Phase 3 trial mandates the 2mg start. Follow the evidence.

Mistake 2: Escalating too fast because results seem slow. Weight loss at 2mg is modest by design. The starting dose is about GI adaptation, not maximum fat loss. Jumping to 8mg at week 5 because you only lost 3 pounds sets you up for severe nausea and potential protocol abandonment.

Mistake 3: Injecting more than once per week. Retatrutide's half-life is approximately 6 days. A single weekly injection maintains therapeutic blood levels continuously. Injecting twice per week does not double the benefit. It doubles the side effects and waste.

Mistake 4: Miscalculating concentration after reconstitution. A 10mg vial reconstituted in 1mL gives 10mg/mL. The same vial reconstituted in 2mL gives 5mg/mL. Confusing these two concentrations means injecting half or double your intended dose. Always label your vial with the exact concentration immediately after reconstitution. Use the peptide reconstitution calculator to verify your math.

Mistake 5: Using sterile water instead of bacteriostatic water. Sterile water has no preservative. Bacteria colonize the vial within 24 to 48 hours. By your second weekly injection, you may be injecting a contaminated solution. Always use bacteriostatic water (0.9% benzyl alcohol). For more on the difference, see is reconstitution solution the same as bacteriostatic water.

Mistake 6: Leaving the vial at room temperature. Every minute your reconstituted vial spends outside the fridge reduces potency. Over a month of daily room-temperature exposure (pulling it out, forgetting it on the counter for 30 minutes), cumulative degradation becomes significant. Pull the vial out, draw your dose in under 2 minutes, and return it immediately.

Mistake 7: Shaking instead of swirling. Aggressive shaking denatures the peptide chain through agitation-induced aggregation. The molecules unfold and clump together, reducing potency and potentially creating particles that cause injection site irritation. Always swirl gently.

Mistake 8: Reusing needles. A single-use insulin syringe costs pennies. Reusing a needle introduces bacteria into your vial and into your tissue. The needle tip also dulls after one use, making subsequent injections more painful and more likely to cause tissue damage. Use a fresh syringe for every injection. For more on injection supplies and safety, see getting started with peptides.